Find Peptide Clinics
Clinic partner placement is available in select cities.View listing options

MOTS-c Benefits: FDA Read the Same Papers and Found No Human Data

Find Peptide Clinics Editorial Desk

The MOTS-c benefits on a clinic page come from mice. That is the entire distance between the sales pitch and the paperwork, and this year the FDA’s own reviewers wrote it down in a briefing document that runs 44 pages.

Here is the direct answer: no published human study has measured a MOTS-c benefit, and the reviewers who examined the same animal papers concluded there is a lack of evidence to evaluate the effectiveness of the substance for any use its seller nominated.

We pulled that document, the two founding papers, and both human trial records. The rest of this page separates what the mouse work shows from what a vial in a clinic fridge can show.

MOTS-c Benefits: The Promise On The Page

Sellers describe a mitochondrial peptide that turns on AMPK, the cell’s energy sensor, and behaves like exercise in a vial. The claims arrive in a stack: better insulin sensitivity, easier fat loss, more endurance, denser bone, slower aging.

Those claims trace to a real discovery. Lee and colleagues reported in Cell Metabolism in March 2015 (volume 21, pages 443-454) a 16-amino-acid peptide translated from a short open reading frame inside the mitochondrial 12S rRNA. Its apparent primary target tissue sits in skeletal muscle. It inhibits the folate cycle and the purine pathway attached to it, which switches on AMPK. The paper’s own sentence about the results is narrow and specific: treatment prevented age-dependent and high-fat-diet-induced insulin resistance in mice, plus diet-induced obesity.

Prevention in a mouse colony. Hold that phrase, because it does the heavy lifting for everything sold under this name.

The Mouse Numbers Behind MOTS-c Benefits

Strip the adjectives and the numbers are modest and nonhuman.

In the founding work, adult male CD-1 mice on a 60 percent fat diet received MOTS-c at 0.5 mg per kilogram per day into the abdominal cavity for eight weeks. Treated animals weighed roughly 20 percent less than untreated animals eating the same diet, and their hyperinsulinemia fell. A second experiment gave 5 mg per kilogram per day and measured a glucose infusion rate about 30 percent higher during insulin stimulation. A third restored insulin sensitivity in 12-month-old mouse muscle to levels seen in 3-month-old mice.

Reynolds and colleagues added the endurance story in Nature Communications in January 2021 (volume 12, article 470). Old mice treated at 15 mg per kilogram per day for two weeks ran 2-fold longer and 2.16-fold farther on a treadmill. Seventeen percent of treated old mice reached the final sprint stage, against none of the untreated old mice. The same paper ran intermittent dosing at 15 mg per kilogram three times a week from 23.5 months of age and reported a lifespan difference: median 970 days against 912, maximal 1120 against 1047.

Read the units again. Milligrams per kilogram of mouse, delivered into the peritoneal cavity, under an animal protocol. No published study converts any of that into a human injection.

The One Human Trial, And What It Measured

One completed study gave a MOTS-c-shaped molecule to people. It tested CB4211, an analog built by CohBar, and the registry record tells you what it asked.

ClinicalTrials.gov updated that record on 11 May 2021. NCT03998514 was a Phase 1a/1b study in healthy non-obese volunteers and people with nonalcoholic fatty liver disease. It enrolled 88 participants, started 9 July 2018, and completed 19 April 2021. The primary outcomes listed are adverse event incidence and severity, clinical laboratory values, vital signs, twelve-lead ECG parameters, physical examinations, and injection-site assessments. Pharmacokinetics sit in the secondary column.

Safety and blood levels. No efficacy endpoint appears in the primary set, so the study was built to answer whether the molecule hurt anyone, not whether it helped.

A second trial now runs in the other direction. NCT07505745, sponsored by Hudson Biotech, began recruiting 2 February 2026 with 120 adults planned. It measures insulin sensitivity by the Matsuda Index and treatment-emergent adverse events as co-primary outcomes, using a fixed dose once daily for twelve weeks. Its results do not exist yet.

What FDA’s Own Reviewers Wrote

In a briefing document dated 11 May 2026, FDA scientists evaluated MOTS-c for the 503A bulks list. Wells Pharmacy Network filed the nomination and later withdrew it. The agency kept going anyway, on its own initiative.

The document states that its literature search turned up no published study giving a compounded or non-compounded MOTS-c drug product to a human. It adds that outsourcing facilities reported preparing no such products to the agency between January 2017 and December 2025.

Then the section on effectiveness, in the agency’s own words: nonclinical studies “were limited to in-vitro and in-vivo rodent models,” assessments of dose-response are “missing,” the molecular targets “remains unknown,” and “the clinical relevance of the findings of these nonclinical studies is currently unknown.”

The conclusion lands flat. “There is a lack of evidence to evaluate the effectiveness of the MOTS-c-related BDSs for the nominated uses.” The agency also noted that FDA-approved drugs already exist for weight reduction in obesity and for osteoporosis, the two uses it examined.

On characterization, reviewers could not rule out immunogenicity from peptide aggregates and impurities, and flagged inconsistent naming across products sold under the same name. The recommendation: do not add MOTS-c to the list.

One more line deserves daylight. FDA observed that MOTS-c appears as a prohibited substance in the Global DRO database, sourced from the 2024 WADA Prohibited List of Hormone and Metabolic Modulators. A peptide sold for metabolic performance sits on the anti-doping list for the pathway it activates.

The Committee Voted The Other Way

The Pharmacy Compounding Advisory Committee met on 23 July 2026 and discussed MOTS-c for obesity and osteoporosis. Trade coverage of that session, including the American Journal of Managed Care’s report on 24 July 2026, put the tally at 7 to 5 with two abstentions in favor of recommending inclusion, against the staff recommendation.

A recommendation is not a rule. FDA’s own meeting page describes committee advice as non-binding. Nothing about that vote makes a compounded MOTS-c product legal, approved, or studied in humans. A proposed rule, a comment period, and a final rule would each have to follow before a pharmacy could compound it lawfully, and none of that has happened.

Our DailyMed check on 23 October 2026 returned zero label records for MOTS-c. No approved product means no label, no indication, no contraindication list, and no regulator-reviewed dose.

What A Clinic Selling It Today Cannot Show You

Ask for four things, in this order.

A completed human trial of the actual molecule with a clinical endpoint. It does not exist. The analog trial measured safety.

A published dose that produces a measurable blood level in people. The registry hides the milligrams behind “fixed dose.”

A rate of adverse events in humans. That number is the primary outcome of a trial still recruiting.

A product a regulator reviewed. There is none.

Compounded MOTS-c is not an FDA-approved drug, and it is not the material used in the published animal work. Doses vary by prescriber and by pharmacy, which is why we publish no protocol and point you to the prescriber who signs the order. For the dosing record in detail, read our piece on why MOTS-c has no established human dose.

For what the agency said about the wider peptide shelf, our summary of the FDA safety list of 17 withdrawn peptides covers the same regulatory machinery. The plain-language version of whether peptides are safe explains why the vial matters more than the name.

Frequently Asked Questions

What benefits of MOTS-c are proven in humans?

None. No published human study has measured a clinical benefit from MOTS-c, and FDA reviewers wrote in May 2026 that the supporting work was limited to cells and rodents.

Where do the MOTS-c benefit claims come from?

Mouse studies. Weight, insulin sensitivity, treadmill endurance, and a lifespan difference have all been reported in rodents, and none has been reproduced as a treatment effect in people.

Is MOTS-c approved by the FDA?

No. It is not a component of any FDA-approved drug, no label exists for it, and in July 2026 the agency proposed not adding it to the 503A compounding list.

Did the FDA committee recommend MOTS-c?

The Pharmacy Compounding Advisory Committee reportedly voted 7 to 5 with two abstentions in favor on 23 July 2026. That advice is non-binding and did not change the legal status of the substance.

Has MOTS-c ever been tested in people?

One completed trial gave 88 participants an analog called CB4211, and its primary endpoints were safety, laboratory values, and pharmacokinetics. A second trial of MOTS-c itself began recruiting in February 2026 and has published nothing.

Is MOTS-c banned in sport?

FDA’s briefing document notes that MOTS-c appears as a prohibited substance on the Global DRO database, drawn from the 2024 WADA Prohibited List of Hormone and Metabolic Modulators.

What should you ask a clinic selling MOTS-c?

Ask for a completed human trial of the molecule with a clinical endpoint, and ask which pharmacy compounds it and under whose license. A clinic that cannot name those has nothing behind the claim.

Sources:

This article reports published research and regulatory documents. It is not medical advice, and it is not a recommendation for or against any product. Compounded substances are not FDA-approved, and doses, risks, and suitability vary by person. Talk to a licensed prescriber about your own situation before you start, stop, or pay for anything.